Related Experiment Videos
Adalimumab therapy for childhood uveitis
Liza B Vazquez-Cobian1, Thomas Flynn, Thomas J A Lehman
1Division of Pediatric Rheumatology, Hospital for Special Surgery, New York, New York 10021, USA.
The Journal of Pediatrics
|October 3, 2006
Summary
Adalimumab treatment effectively reduced inflammation in pediatric uveitis patients. The study found significant improvement in most eyes with no major adverse events, highlighting its potential therapeutic benefit.
Area of Science:
- Ophthalmology
- Rheumatology
- Pediatrics
Background:
- Uveitis in children, including Juvenile Idiopathic Arthritis (JIA)-associated and idiopathic forms, presents a significant challenge.
- Current treatment options may have limitations or side effects.
- Adalimumab, a biologic agent, has shown promise in adult uveitis but requires evaluation in pediatric populations.
Purpose of the Study:
- To evaluate the efficacy and safety of adalimumab in treating pediatric uveitis.
- To assess the impact of adalimumab on ocular inflammation in children with JIA-associated and idiopathic uveitis.
Main Methods:
- A cohort of 14 children with uveitis (9 with JIA, 5 idiopathic) was treated with adalimumab.
- Treatment duration averaged 18.1 months.
- Ocular inflammation and adverse events were monitored throughout the study period.
Main Results:
- Significant reduction in ocular inflammation was observed in 80.8% of eyes (21/26).
- 15.4% of eyes (4/26) remained stable, and only 3.8% (1/26) showed worsening.
- No significant adverse events were reported during the treatment period.
Conclusions:
- Adalimumab demonstrates significant efficacy in reducing ocular inflammation in pediatric uveitis patients.
- The treatment appears well-tolerated in this pediatric cohort.
- Adalimumab represents a promising therapeutic option for managing childhood uveitis.
Related Concept Videos
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
01:27Open Angle Glaucoma: Treatment
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
01:28Angle Closure Glaucoma: Treatment
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...